Cargando…

Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases

INTRODUCTION: The effect of nintedanib on slowing the rate of decline in forced vital capacity (FVC) has been investigated in randomized placebo-controlled trials in subjects with idiopathic pulmonary fibrosis (IPF), other progressive fibrosing interstitial lung diseases (ILDs), and ILD associated w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bonella, Francesco, Cottin, Vincent, Valenzuela, Claudia, Wijsenbeek, Marlies, Voss, Florian, Rohr, Klaus B., Stowasser, Susanne, Maher, Toby M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239974/ https://www.ncbi.nlm.nih.gov/pubmed/35576048 http://dx.doi.org/10.1007/s12325-022-02145-x

Ejemplares similares

Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
por: Cottin, Vincent, et al.
Publicado: (2021)

Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2022)

Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
por: Bonella, Francesco, et al.
Publicado: (2015)

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
por: Wollin, Lutz, et al.
Publicado: (2019)

Effect of Nintedanib on Progression of Systemic Sclerosis‐Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial
por: Assassi, Shervin, et al.
Publicado: (2022)

Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials
por: Kreuter, Michael, et al.
Publicado: (2020)

Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials
por: Noth, Imre, et al.
Publicado: (2019)

Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial
por: Flaherty, Kevin R., et al.
Publicado: (2022)

Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK®trial
por: Maher, Toby M, et al.
Publicado: (2018)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

Nintedanib in children and adolescents with fibrosing interstitial lung diseases
por: Deterding, Robin, et al.
Publicado: (2023)

Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial
por: Noth, Imre, et al.
Publicado: (2021)

Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives
por: Kreuter, Michael, et al.
Publicado: (2015)

The world of rare interstitial lung diseases
por: Buschulte, Katharina, et al.
Publicado: (2023)

Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib
por: Woodcock, Hannah V, et al.
Publicado: (2013)

Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme
por: Valenzuela, Claudia, et al.
Publicado: (2020)

Impact of chronic fibrosing interstitial lung disease on healthcare use: association between fvc decline and inpatient hospitalization
por: Singer, David, et al.
Publicado: (2023)

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)
por: Richeldi, Luca, et al.
Publicado: (2023)

Effects of nintedanib by inclusion criteria for progression of interstitial lung disease
por: Maher, Toby M., et al.
Publicado: (2022)

Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use
por: Kreuter, Michael, et al.
Publicado: (2021)

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
por: Flaherty, Kevin R., et al.
Publicado: (2018)

Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease
por: Deterding, Robin, et al.
Publicado: (2021)

Fibrosing interstitial lung diseases: knowns and unknowns
por: Cottin, Vincent, et al.
Publicado: (2019)

SVC Is a Marker of Respiratory Decline Function, Similar to FVC, in Patients With ALS
por: Pinto, Susana, et al.
Publicado: (2019)

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
por: Wollin, Lutz, et al.
Publicado: (2015)

Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era
por: Nakshbandi, Gizal, et al.
Publicado: (2021)

Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?
por: Kalluri, Meena, et al.
Publicado: (2021)

Risk Stratifying Interstitial Lung Abnormalities to Guide Early Diagnosis of Interstitial Lung Diseases
por: Wijsenbeek, Marlies S., et al.
Publicado: (2022)

Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
por: Ryerson, Christopher J., et al.
Publicado: (2019)

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2020)

Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial
por: Matteson, Eric L., et al.
Publicado: (2022)

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
por: Khanna, Dinesh, et al.
Publicado: (2023)

Forced Vital Capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis
por: Lassenius, Mariann I., et al.
Publicado: (2019)

Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases
por: Brown, Kevin K., et al.
Publicado: (2022)

Talaromycosis in a Patient on Nintedanib for Interstitial Lung Disease
por: Madgula, Anantha Sriharsha, et al.
Publicado: (2020)

Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
por: Lamb, Yvette N.
Publicado: (2021)

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
por: Seibold, James R, et al.
Publicado: (2020)

A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease
por: Maher, Toby M., et al.
Publicado: (2022)

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)
por: Maher, Toby M, et al.
Publicado: (2023)

Rapid FEV(1)/FVC Decline Is Related With Incidence of Obstructive Lung Disease and Mortality in General Population
por: Choi, Kwang Yong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1mkgellu04gbhu151dldi2gamb